Business
CB2 Insights Launches Industry’s First Medical Cannabis Insights Dashboard for All Medical Cannabis Stakeholders
CB2 Insights Launches Industry’s First Medical Cannabis Insights Dashboard for All Medical Cannabis Stakeholders.
About this update from Skylight Health Group Inc.
[{"type":"text","content":"\n TORONTO, March 30, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has launched the medical cannabis industry’s first interactive dashboard which gives any industry stakeholders access to key patient insights derived from the Company’s clinical operations. The tool (link: https://cb2insights.ca/data) is free to use and was created in order to answer hundreds of inbound questions from global industry stakeholders including government agencies and major research groups. The dashboard also allows users to submit additional data requests directly to the Company’s research and data team. “Over the last several months, we have seen hundreds of requests for data and insights from stakeholders such as government bodies, researchers, pharma companies, physicians, hospital networks, cultivators, and the list goes on,” said Prad Sekar, CEO of CB2 Insights.  “This new interactive tool will allow these groups to access the primary insights that they are requesting quickly and gain real-time results.  But with the millions of data points that we monitor, they also have the opportunity to discuss with us how they can receive more tailored results that match their needs. And more importantly, solidify CB2 Insights as one of the sole providers of these types of insights in this industry.” The tool provides users with the ability to filter results of over hundreds of thousands of anonymized de-identified clinical interactions in categories such as primary medical condition, age grouping, previous cannabis experience, other medication being used, cannabinoid profile usage and the patient’s positive and negative effects of their cannabis treatment. With millions of datapoints, the Company has the ability to provide an unparalleled  amount of customized insights to stakeholders. “Accurate, structured data is at the center of everything healthcare companies do in this day and age,” said Tom Brogan, Director, CB2 Insights and former IQVIA Executive. “Access to the type of medical cannabis data that CB2 holds is not only rare, it is essential to truly transition these alter...